Top Story Today
Novo Nordisk's Obesity Blockbuster-in-Waiting Just Got Humbled on the Biggest Stage
CagriSema, the combination drug Novo Nordisk hoped would reclaim the obesity throne from Eli Lilly, failed its head-to-head Phase 3 trial against Zepbound. Patients on Zepbound lost 25.5% of their body weight versus 23.0% for CagriSema, a gap wide enough that Novo's drug couldn't even prove it was "basically just as good." Novo's stock plunged 15% while Lilly climbed 5%. Goldman Sachs slashed CagriSema sales forecasts by 65%, and analysts now describe the injectable obesity market as winner-takes-most, with Lilly firmly in control.
Why it matters: With Lilly's tirzepatide franchise already pulling in $36.5 billion annually and CagriSema accounting for up to 60% of Novo's projected future growth, this loss doesn't just reshape one company's pipeline; it tilts the most commercially important drug market in a generation decisively toward Lilly.
Read more →Deals and M&A
Ipsen Bets $1.75 Billion on a Blood Cancer Drug That Hasn't Finished Its Pivotal Trial
Ipsen is acquiring Kartos Therapeutics for up to $1.75 billion, but 74% of the deal's value hinges on milestones tied to regulatory approval and commercial sales targets, with Phase 3 data not expected until 2027. The prize is navtemadlin, an oral pill designed to combine with Jakafi for myelofibrosis patients who aren't responding well enough. Big pharma is circling this space aggressively, with multiple companies making significant myelofibrosis acquisitions.
Read more →A 'Masked' Cancer Drug Just Fooled Its Way Into a $1.7 Billion Prostate Cancer Deal
Vir Biotechnology's VIR-5500, an antibody that stays hidden until it reaches a tumor, posted an 82% PSA response rate and 45% tumor shrinkage in heavily pretreated prostate cancer patients, with mostly Grade 1 cytokine release syndrome primarily seen in the first cycle. Astellas liked those numbers enough to pay $240 million upfront (plus a $75 million equity stake) with up to $1.7 billion total on the table.
Read more →Clinical and Regulatory
Sarepta Adds the FDA's Most Severe Warning to Its Gene Therapy, Then Cuts 36% of Staff
Two teenage boys died of liver failure after receiving Elevidys, prompting a black box warning and restricted use to ambulatory patients only. Sarepta simultaneously laid off 500 workers and paused most limb-girdle gene therapy programs, aiming to save $400 million annually. The stock has fallen over 80% from its highs, and management says $500 million in annual Elevidys sales is the minimum to stay solvent.
Read more →AstraZeneca's Next-Gen Bone Disease Drug Crushed Pediatric Trials, Then Missed in Adults
Efzimfotase alfa, designed to replace the $1.15 billion-a-year Strensiq franchise, hit every endpoint in kids with a rare bone mineralization disease. But in adults and adolescents, it failed to beat placebo on the six-minute walk test. AstraZeneca's projected $3 to $5 billion peak sales now need a serious haircut on the adult side.
Read more →One Pill for ADHD and Anxiety? Otsuka's Phase 3b Data Says It's Possible.
Centanafadine, a triple reuptake inhibitor, hit statistically significant endpoints on both ADHD symptoms and anxiety in 315 adults carrying both diagnoses. No other non-stimulant has dedicated Phase 3 data in this population. The FDA's approval decision lands July 24, and the anxiety data could give this drug a unique positioning in a market dominated by stimulants.
Read more →Pipeline Moves
Novartis Tested a Cancer Drug on 30 Patients. Not One Tumor Shrank.
QEQ278, designed to unmask tumors for immune system attack, went 0-for-30 in its Phase 1 trial before Novartis pulled the plug. Twenty-six of those patients actually progressed on the drug. It's a quiet footnote, but it fits a pattern: Novartis axed six Phase 1 oncology programs in late 2025 as it concentrates firepower on blockbusters like Kisqali and Pluvicto.
Read more →Lilly Caps Every Zepbound Dose at $449 per Month, Completing Its GLP-1 Price War Playbook
Lilly is selling the two highest Zepbound doses (12.5 and 15 mg) in single-dose vials through LillyDirect, capping every strength at $449 or less. That's roughly half the cost of standard autoinjector pens. With traditional Medicare Part D still barred from covering obesity drugs—though the new Medicare GLP-1 Bridge program offers limited coverage at $50/month—and commercial coverage actually shrinking, Lilly is building a direct-to-consumer side door that already has over a million users.
Read more →